Canada markets open in 4 hours 45 minutes
  • S&P/TSX

    19,321.92
    +150.26 (+0.78%)
     
  • S&P 500

    4,170.42
    +45.76 (+1.11%)
     
  • DOW

    34,035.99
    +305.10 (+0.90%)
     
  • CAD/USD

    0.7989
    +0.0012 (+0.15%)
     
  • CRUDE OIL

    63.51
    +0.05 (+0.08%)
     
  • BTC-CAD

    77,189.69
    -2,046.17 (-2.58%)
     
  • CMC Crypto 200

    1,373.28
    -7.66 (-0.55%)
     
  • GOLD FUTURES

    1,766.50
    -0.30 (-0.02%)
     
  • RUSSELL 2000

    2,257.07
    +9.35 (+0.42%)
     
  • 10-Yr Bond

    1.5300
    0.0000 (0.00%)
     
  • NASDAQ futures

    13,970.75
    -43.25 (-0.31%)
     
  • VOLATILITY

    16.67
    -0.32 (-1.88%)
     
  • FTSE

    7,011.41
    +27.91 (+0.40%)
     
  • NIKKEI 225

    29,683.37
    +40.68 (+0.14%)
     
  • CAD/EUR

    0.6669
    +0.0011 (+0.17%)
     

Tricida to Present at the Needham Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Tricida, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 12:45 pm PT / 3:45 pm ET. Tricida will provide a company overview, business update and progress on the company’s key initiatives.

A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows progression of CKD in patients with metabolic acidosis and CKD. There are no FDA-approved treatments for chronic metabolic acidosis, a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.tricida.com.

Contact:

Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com